CD19-targeted CAR T-cell therapy shows a 65% response rate in Richter transformation, with median progression-free survival of 8 months and overall survival of 14.4 months. Early response and age are ...
B-cell depletion with unconjugated CD20 monoclonal antibody (mAb) is used to treat rheumatoid arthritis and other autoimmune diseases. CD20-targeted immunotherapy depletes mature B cells through ...
In the ongoing SENTRY-CD19 trial, all three anti-AAV antibody-naïve patients with relapsed/refractory acute lymphoblastic leukemia (ALL) have ...
SYDNEY & DUARTE, Calif.--(BUSINESS WIRE)--Imugene Ltd (ASX:IMU), an immuno-oncology company and City of Hope, a world-renowned independent cancer research and treatment center near Los Angeles, today ...
Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial This phase II trial enrolled 225 evaluable ...
Researchers from The University of Texas MD Anderson Cancer Center have reported promising results in a Phase I/II trial of 37 patients with relapsed or refractory B-cell malignancies who were treated ...
Los Angeles, USA, May 10, 2021 (GLOBE NEWSWIRE) -- Anti-CD19 Antibody Pipeline Report, 2021 Featuring TG Therapeutics, Merck kGaA, Generium Pharmaceutical, Sanofi, Incyte Corporation, Amgen, Viela ...
Impact of Organ Function–Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind? Fifty CAYAs with B-ALL were treated (median age, 13.5 years; ...
New research has uncovered the previously unknown presence of CD19 -- a B cell molecule targeted by chimeric antigen receptor (CAR) T cell immunotherapy to treat leukemia, lymphoma, and multiple ...
Inebilizumab's twice-yearly CD19 dosing directly targets antibody-producing cells; trial enrollment used disease activity, ...
UPLIZNA growth is driven by new indications, global expansion, strong efficacy, differentiated CD19 targeting and twice-yearly dosing, though competition is intensifying.Dublin, Sept. 24, 2026 (GLOBE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results